What they were paid
ALX ONCOLOGY Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $1,831 | — | $0 | $598,958 | $600,789 |
| FY2024 | $13,661 | — | $82,978 | — | $96,639 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ALX ONCOLOGY HOLDINGS INC DEF 14A filed April 20, 2026, accession 0001193125-26-163936, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025ALX ONCOLOGY pays directors a $40,000 cash retainer.
The rest of the ALX ONCOLOGY board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Chris Takimoto, M.D., Ph.D., F.A.C.P | Independent Director | $98,864 |
| Corey Goodman, Ph.D | Chair of the Board | $147,871 |
| Daniel Curran, M.D | Independent Director | $38,973 |
| Jason Lettmann | Director | $0 |
| Rekha Hemrajani | Independent Director | $115,011 |
| Scott Garland | Independent Director | $113,511 |
The full ALX ONCOLOGY compensation record
free company briefThis page is one director within ALX ONCOLOGY's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat